RxSight (RXST) Common Equity (2020 - 2026)

RxSight's Common Equity history runs 7 years deep, the most recent figure standing at $267.3 million for Q1 2026.

• Quarterly Common Equity fell 4.3% year-over-year to $267.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $267.3 million (down 4.3% YoY) and the FY2025 annual result came in at $275.7 million, down 1.98% from the prior year.
• Common Equity was $267.3 million for Q1 2026 at RxSight, down from $275.7 million in the prior quarter.
• Across five years, Common Equity topped out at $281.2 million in Q4 2024 and bottomed at $89.9 million in Q4 2022.
• A 5-year average of $201.0 million and a median of $163.9 million in 2024 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 140.8% in 2022, while the deepest fall reached 36.41% in 2022.
• RxSight's Common Equity stood at $89.9 million in 2022, then soared by 78.37% to $160.4 million in 2023, then soared by 75.38% to $281.2 million in 2024, then fell by 1.98% to $275.7 million in 2025, then fell by 3.04% to $267.3 million in 2026.
• Business Quant data shows RXST's Common Equity at $267.3 million in Q1 2026, $275.7 million in Q4 2025, and $276.0 million in Q3 2025.